This is a medicine used to treat HIV infection. It works by stopping the virus from multiplying. It's often taken as part of a combination therapy with other HIV medications.
Every report comes from a Lived member, sent anonymously.
Have you tried Viramune (Nevirapine) for HIV Infection?
Nevirapine is a prescription HIV medicine. It was sold in the US as Viramune and Viramune XR, brands that have since been discontinued; generic nevirapine tablets, extended-release tablets and an oral liquid remain available. It treats HIV-1, the most common type of HIV, and is always used as part of a combination of HIV medicines. The regular tablets and the liquid are approved for adults and for children from 15 days of age. The extended-release tablets are approved for adults and for children 6 and older who are large enough for the full tablet. Nevirapine is no longer a usual first choice. Because of a risk of serious liver injury, its label advises against starting it, unless the benefit clearly outweighs the risk, in women whose CD4 count is above 250 or men whose count is above 400. CD4 cells are the immune cells HIV damages, and the count (cells per cubic millimeter of blood) reflects how strong the immune system is. A higher count when nevirapine is started is linked to a higher chance of a liver reaction. The World Health Organization recommends dolutegravir, a newer HIV medicine from a different class, as the preferred treatment, noting rising HIV resistance to nevirapine-based regimens.
To copy itself, HIV has to turn its genetic material (RNA) into DNA that can be built into an infected cell. It does this with an enzyme called reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor, or NNRTI: it attaches directly to this enzyme and disrupts the part that does the work. With fewer new copies of the virus being made, the amount of HIV in the blood (the viral load) falls. That gives the immune system a chance to recover and lowers the risk of AIDS and HIV-related illnesses, though it does not cure HIV. Nevirapine acts on HIV-1 but not on HIV-2. It only works well in combination with other HIV medicines, because the virus can quickly become resistant to nevirapine used alone, and that resistance can carry over to other medicines in the same class.
Nevirapine is taken by mouth, with or without food. Every new course starts with a two-week lead-in: one 200 mg regular tablet once a day for the first 14 days. This lower starting dose was shown to reduce the chance of rash. After that, adults usually take either a 200 mg tablet twice a day or one 400 mg extended-release tablet once a day. Children's doses are worked out from their body size. If a rash appears during the lead-in, the dose is not increased until the rash has cleared, and the once-daily lead-in is not continued beyond 28 days; at that point a different regimen is considered. If nevirapine is stopped for more than seven days, the two-week lead-in has to be repeated, so check with the prescriber before restarting after a break. Extended-release tablets must be swallowed whole, never chewed, crushed or split. Regular and extended-release nevirapine are never taken together, because that would be an overdose. If a dose is missed, take the next dose as soon as possible, but do not double up. Taking every dose matters: when doses are missed, the virus can multiply and become resistant to the medicines.
Rash is the most common side effect. In clinical trials it affected about 15 in 100 adults taking nevirapine, compared with 6 in 100 taking a placebo. Most of these rashes are mild to moderate, red and sometimes itchy, on the trunk, face, arms or legs, and they usually appear in the first six weeks. Nausea and changes in liver blood tests also occur. Report any new rash in the first 18 weeks to the prescriber promptly, even a mild one, because it calls for an immediate liver blood test. Nevirapine carries the FDA's most serious type of warning, a boxed warning, for two reactions that can be life-threatening. Both are most likely in the first six weeks, remain more likely through 18 weeks, and can happen later. Stop nevirapine and get medical care right away for signs of liver injury, such as yellow skin or eyes, dark urine, pale stools, pain or tenderness under the right ribs, or unexplained tiredness, nausea or loss of appetite. Do the same for a severe skin or allergic-type reaction: a rash together with fever, blisters, mouth sores, red or swollen eyes, facial swelling, or muscle or joint aches. Liver reactions are more likely in women, in people who start with a higher CD4 count, and in people who also have hepatitis B or C. After either reaction, nevirapine is not restarted, and in some cases liver damage has continued to worsen even after it was stopped.
Nevirapine speeds up liver enzymes that break down many other medicines, so it can lower their levels, and some medicines change nevirapine levels in turn. The combinations that matter most are these. Rifampin, an antibiotic used for tuberculosis, lowers nevirapine levels and is not used with it; rifabutin is an alternative. St. John's wort, an herbal supplement, can lower levels enough for treatment to fail and resistance to develop. Methadone levels drop, so people on methadone may notice withdrawal symptoms and need a dose adjustment. Warfarin, a blood thinner, needs more frequent clotting checks. Several HIV medicines, including atazanavir and other NNRTIs such as efavirenz, are not combined with it, and the antifungals ketoconazole and itraconazole are avoided. Prednisone, a steroid, should not be used to try to prevent the rash, because it made rash more common in a trial. Give the prescriber and pharmacist a full list of medicines and supplements. Nevirapine is not used by people with moderate or severe liver disease, and people with milder liver scarring need closer monitoring. It must not be used for post-exposure prophylaxis (PEP), the short course of HIV medicines taken after a possible exposure, because people without HIV have developed serious liver damage when given it for this purpose. In pregnancy, registry data have not shown more birth defects than expected, but serious liver reactions have occurred in pregnant women, and the same CD4 limits apply to starting it. People taking nevirapine are advised not to breastfeed: it passes into breast milk, and breastfeeding can pass HIV to the baby. Published reports suggest combined birth control pills still prevent pregnancy when taken with nevirapine.
The first 18 weeks are the period of closest watch. Liver blood tests are done before starting and frequently during this time; many experts check them before the dose goes up after the lead-in and again two weeks later, with clinical and lab checks more than once a month. Monitoring continues at regular intervals for as long as nevirapine is taken. The aim of HIV treatment is to bring the viral load down and keep it there, which is tracked with regular viral load and CD4 tests. Nevirapine does not cure HIV, and HIV treatment is long-term, so stopping or switching is planned with the care team. That planning matters with nevirapine in particular: it stays in the body for a week or longer, so if all HIV medicines are stopped at once, nevirapine can be left working alone and the virus can become resistant. As the immune system recovers early in treatment, it sometimes reacts to infections that were already in the body, causing new fever or other symptoms. This is called immune reconstitution syndrome. Tell the care team promptly about any signs of infection after starting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Viramune (Nevirapine), what you've noticed, or ask the community a question.